Search
Bromfenac
go.drugbank.com/drugs/DB00963ApprovedWithdrawnNon-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation.
Riltozinameran
go.drugbank.com/drugs/DB17095ApprovedInvestigationalBA.4, BA.5) which, although similar, may behave differently from one another.[L43917] Riltozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineage BA.1. … The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021.
Mixtures: Comirnaty Original/omicron Ba.1Nortriptyline
go.drugbank.com/drugs/DB00540ApprovedInvestigationalNortriptyline hydrochloride, the active metabolite of [amitriptyline], is a tricyclic antidepressant (TCA).
Categories: Dopamine D2 Receptor Antagonists, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamineTrifluridine
go.drugbank.com/drugs/DB00432ApprovedInvestigationalIt is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. … Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine] [A35271].
YKP-1358
go.drugbank.com/drugs/DB06109ExperimentalYKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. … In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.
Categories: Dopamine D2 Receptor AntagonistsSomatrogon
go.drugbank.com/drugs/DB14960ApprovedInvestigational[L39362] In October 2021, Health Canada approved somatrogon under the market name NGENLA as the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous … Somatrogon is a long-acting recombinant human growth hormone.
Nateglinide
go.drugbank.com/drugs/DB00731ApprovedApproximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. … Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose.
Mixtures: NAT-ALA 120/200 MG FILM KAPLI TABLET, 90 ADET, NAT-ALA 180/200 MG FILM KAPLI TABLET, 90 ADETLevacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. … Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic IndexMethylparaben
go.drugbank.com/drugs/DB14212ApprovedMethylparaben is used in allergenic testing.
Mixtures: CLISMA LAX, CLISMA LAXCategories: Compounds used in a research, industrial, or household settingDiatrizoate
go.drugbank.com/drugs/DB00271ApprovedVet approvedA commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
Mixtures: Sinografin - Liq Iu, MD- GASTROVIEW® (MEDIO DE CONTRASTE PARA RADIOGRAFIA)Categories: Compounds used in a research, industrial, or household setting